// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

USAGE PATTERN OF CONCOMITANT THERAPY WITH BIOLOGICAL DMARDS IN CHINESE PATIENTS WITH RHEUMATOID ARTHRITIS: A MULTI-CENTER CROSS-SECTIONAL STUDY

T. Liu - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

MEDICATION ADHERENCE IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS

L. Barbosa - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Rheumatoid arthritis

Hydroxychloroquine

ENDOCARDITIS IN PATIENTS UNDER IMMUNOSUPPRESSIVE TREATMENT: DO-T STOP BELIEVI-

F. Pulvirenti - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

NEGLECTED INHABITANT IN RHEUMATIC IMMUNOSUPPRESSED PATIENTS: A REPORT OF FOUR CASES OF STRONGYLOIDIASIS

N. Khmelinskii - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

Hydroxychloroquine

HYDROXYCHLOROQUINE IN THE SYMPTOMATIC CONTROL OF EROSIVE HAND OSTEOARTHRITIS

N. Cid Boza - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hypercholesterolemia, Familial, 1

Hydroxychloroquine

MEASURING MICROARCHITECTURE BONE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. PILOT STUDY

N. Mena-Vazquez - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

DRUGS CAUSING MUSCLE DISEASE

A. Mammen - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cap myopathy

Hydroxychloroquine

THE TREATMENT APPROACH FOR THE MANAGEMENT OF REMITTING SERONEGATIVE SYMMETRICAL SYNOVITIS WITH PITTING EDEMA (RS3PE) SYNDROME

M. Calis - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

Hydroxychloroquine

RENAL OUTCOMES IN A JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS COHORT EXPERIENCE OF A TERTIARY CENTER

M. Rodrigues - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY DIAGNOSED JIA WITH DIFFERENT TREATMENT STRATEGIES (ACUTE-JIA STUDY)

M. Tarkiainen - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

CYCLOSPORINE IN RESISTANT SYSTEMIC JIA A CHEAPER ALTERNATIVE TO BIOLOGICS FOR DEVELOPING COUNTRIES

P.P. Giri - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

A RARE CASE OF INFANTILE SYSTEMIC LUPUS ERYTHEMATOSUS IN THE FIRST YEAR OF LIFE AND SUCCESSFUL TREATMENT WITH HYDROXYCHLOROQUINE

T. Lutz - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

DESCRIPTION OF A SERIES OF PATIENTS WITH CHILDHOOD RHEUMATOLOGIC DISEASES ASSESSED IN A TRANSITION UNIT OF AN ADULT CENTER

V. Torrente-Segarra - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

SLE AND SS: MATERNAL AND FETAL RISKS: TREATMENT STRATEGIES

B. Bermas - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Preterm premature rupture of the membranes

Hydroxychloroquine

HYDROXYCHLOROQUINE DOES NOT INCREASE PSORIASIS IN PSORIATIC ARTHRITIS: TIME ON DRUG ANALYSIS BASED ON REAL LIFE DATA

S.Z. Aydin - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Hydroxychloroquine

ROMANIAN REGISTRY OF RHEUMATIC DISEASES: EFFICACY AND SAFETY OF BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS

C. Codreanu - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Rheumatoid arthritis

Hydroxychloroquine

PERSISTENCE AND ADHERENCE WITH TRIPLE THERAPY AND TUMOR NECROSIS FACTOR INHIBITOR-METHOTREXATE COMBINATION THERAPY IN US VETERANS WITH RHEUMATOID ARTHRITIS

G.W. Cannon - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

IMPACT OF COMBINATION ETANERCEPT-DMARD INDUCTION THERAPY IN ACTIVE RHEUMATOID ARTHRITIS: INTERIM RESULTS OF AN INTERNATIONAL TREAT-TO-TARGET STUDY CONDUCTED IN REGIONS WITH LIMITED BIOLOGIC ACCESS

K. Pavelka - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

PREDICTION OF NON-ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS

L. Coupal - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Rheumatoid arthritis

Hydroxychloroquine

USE OF METHOTREXATE IN PATIENTS WITH RECENT ONSET RHEUMATOID ARTHRITIS ALTER SERUM CHOLESTEROL AND TRIGLYCERIDE LEVELS

J. Calvo Gutierrez - European League Against Rheumatism (EULAR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Rheumatoid arthritis

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved